share_log

Johnson & Johnson | SC 13G: Statement of acquisition of beneficial ownership by individuals-Johnson & Johnson(8.8%),Johnson & Johnson Innovation-JJDC, Inc.(8.8%)

Johnson & Johnson | SC 13G: Statement of acquisition of beneficial ownership by individuals-Johnson & Johnson(8.8%),Johnson & Johnson Innovation-JJDC, Inc.(8.8%)

強生 | SC 13G:超過5%持股股東披露文件-Johnson & Johnson(8.8%),Johnson & Johnson Innovation-JJDC, Inc.(8.8%)
美股SEC公告 ·  07/30 21:11
Moomoo AI 已提取核心訊息
Johnson & Johnson, through its subsidiary Johnson & Johnson Innovation-JJDC, Inc., has filed a Schedule 13G with the Securities and Exchange Commission on July 30, 2024, indicating a significant ownership stake in Rallybio Corporation. The filing reveals that JJDC directly owns 3,636,363 shares of Rallybio's Class A Common Stock, which represents 8.8% of the company's class of securities as of April 10, 2024. This ownership percentage is based on the total number of shares outstanding as reported by Rallybio Corporation. Johnson & Johnson, headquartered in New Jersey, and its Delaware-based subsidiary, JJDC, have stated that the shares were not acquired for the purpose of changing or influencing the control of Rallybio Corporation.
Johnson & Johnson, through its subsidiary Johnson & Johnson Innovation-JJDC, Inc., has filed a Schedule 13G with the Securities and Exchange Commission on July 30, 2024, indicating a significant ownership stake in Rallybio Corporation. The filing reveals that JJDC directly owns 3,636,363 shares of Rallybio's Class A Common Stock, which represents 8.8% of the company's class of securities as of April 10, 2024. This ownership percentage is based on the total number of shares outstanding as reported by Rallybio Corporation. Johnson & Johnson, headquartered in New Jersey, and its Delaware-based subsidiary, JJDC, have stated that the shares were not acquired for the purpose of changing or influencing the control of Rallybio Corporation.
強生公司通過其子公司強生創新-JJDC,於2024年7月30日向證券交易所提交了13G表格,表明其在Rallybio公司擁有重要股權。該文件顯示,JJDC直接持有Rallybio公司的3,636,363股A類普通股,佔公司證券類別的8.8%,截至2024年4月10日。這一所有權比例基於Rallybio公司報告的總股本。總部位於新澤西州的強生公司及其位於特拉華州的子公司JJDC表示,該份股份的購買並非爲了改變或影響Rallybio公司的控制權。
強生公司通過其子公司強生創新-JJDC,於2024年7月30日向證券交易所提交了13G表格,表明其在Rallybio公司擁有重要股權。該文件顯示,JJDC直接持有Rallybio公司的3,636,363股A類普通股,佔公司證券類別的8.8%,截至2024年4月10日。這一所有權比例基於Rallybio公司報告的總股本。總部位於新澤西州的強生公司及其位於特拉華州的子公司JJDC表示,該份股份的購買並非爲了改變或影響Rallybio公司的控制權。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息